G

GSK

Develops medicines, vaccines, and consumer health

Chemistry Intern

InternshipDeadline 10/13/26
£26.4k/mo+ Bonus
Bachelor's
Stevenage, UK
HybridThe posting states that full-time on-site work is required.
Biology & BiotechTranslational Research & Bench Biology, Bioprocess & Biomanufacturing

About the job

Requirements
  • Completion of at least two years of an undergraduate degree without graduating before the placement starts.
  • Enrollment at a university in the United Kingdom or Republic of Ireland for the duration of the placement.
  • Written and spoken fluency in English.
  • For Structural and Biophysical Sciences: a degree in Chemistry, Biochemistry, Physics, or Natural Sciences.
  • For Process Chemistry: a degree in Chemistry.
  • For Analytical Development – High Throughput Automation: a degree in Chemistry, Analytical Chemistry, Chemical Engineering, or Pharmaceutical Science.
  • Applicants who already hold a bachelor's degree and are studying a postgraduate master's degree are not eligible.
  • Applicants must complete the Connectr pre-application activity and obtain the required application code.
Responsibilities
  • Work on one of several structural and biophysical techniques, including biophysical assay support, structural biology support, mass spectrometry, or electron microscopy.
  • Work as a laboratory scientist within a multidisciplinary team and deliver individual projects and presentations.
  • Design and conduct laboratory experiments to support chemical process development, applying organic chemistry principles to optimize reaction performance and process understanding.
  • Investigate reaction outcomes, impurity profiles, and process robustness, analyzing scientific data to identify solutions to technical challenges.
  • Support process scale-up activities and technology transfer to pilot plant and manufacturing facilities.
  • Analyze and interpret experimental results and prepare reports communicating findings to project stakeholders.
  • Maintain accurate and compliant laboratory documentation using electronic laboratory notebooks.
  • Collaborate with analytical, engineering, safety, and manufacturing scientists to advance pharmaceutical development and manufacturing objectives.
  • Operate automated equipment, including liquid and solid handlers, multifunctional platforms, and analytical instruments.
  • Employ, optimize, and develop automated workflows to expedite drug development processes.
  • Plan, design, and execute experiments, including data collection and analysis.
  • Use analytical techniques and extract information from large datasets.
Desired Qualifications
  • Previous internship, co-op, or project-focused research experience is not explicitly required in this posting; no separate preferred-qualification list is provided.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Company News

Yahoo Finance
Oct 9th, 2026
GSK to invest $800M in Pennsylvania biopharma hub, creating 300 jobs

GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a biopharmaceutical manufacturing and research hub, creating over 300 jobs in the next five years, Pennsylvania Governor Josh Shapiro's office announced on Friday. The expansion will combine drug manufacturing, research and development, quality testing, and digital operations in Montgomery County. Construction is planned to begin in 2027 and will support clinical and commercial production of biologic medicines. The project will include a commercial-scale biologics manufacturing facility, a research pilot plant, and a centralised quality-control laboratory. It will also retain approximately 4,500 existing full-time jobs in Pennsylvania. Combined with GSK's previously announced Lancaster County facility, the company's planned investment in Pennsylvania totals nearly $1.7 billion.

Global Banking & Finance Review
Oct 9th, 2026
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs.

Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs. Posted on October 9, 2026 · Last updated: October 9, 2026 GSK to invest over $800 million in Pennsylvania biopharma hub, create 300 jobs. GSK's major expansion in Pennsylvania. Overview of the investment. Oct 9 (Reuters) - GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, Pennsylvania Governor Josh Shapiro's office said on Friday. Key features of the new biopharma hub. * The investment will establish a site that combines drug manufacturing, research and development, quality testing and digital operations in Montgomery County. * GSK said construction is planned to begin in 2027 and the project will support both clinical and commercial production of biologic medicines. * The expansion is expected to create more than 300 new jobs and retain about 4,500 existing full-time jobs in Pennsylvania. * The company said the project will include a new commercial-scale biologics manufacturing facility, a research pilot plant and a centralized quality-control laboratory. Economic impact and incentives. * Pennsylvania officials said GSK will be eligible for state manufacturing tax incentives tied to the investment. * The Upper Merion expansion and GSK's previously announced Lancaster County facility project together represent nearly $1.7 billion of planned investment in Pennsylvania, according to state officials. * GSK, whose U.S. headquarters is in Philadelphia, said the expansion will help accelerate the development and supply of future medicines. Reporting credits. (Reporting by Sahil Pandey in Bengaluru; Editing by Anil D'Silva) Key takeaways. * GSK's $800M-plus expansion in Upper Merion expands capabilities across manufacturing, R&D, QC and digital operations and is part of a broader $1.7B investment in PA alongside Lancaster project. * The project supports both clinical and commercial biologic production, with construction slated for 2027, and helps retain more than 4,500 existing Pennsylvania full-time jobs. * State incentives - including manufacturing tax credits - and prior GSK investments in Lancaster contribute to reinforcing Pennsylvania's life-sciences leadership. Frequently asked questions. What is GSK investing in Pennsylvania? How many jobs will GSK's investment create in Pennsylvania? What facilities will be included in GSK's Upper Merion expansion? When is construction expected to begin for GSK's biopharma hub? What incentives is GSK eligible for with this investment?

TokenPost
Oct 9th, 2026
GSK plans more than $800 million expansion in Pennsylvania.

GSK plans more than $800 million expansion in Pennsylvania. The Montgomery County project is expected to add about 300 jobs over the next five years. Published Oct 9, 2026, 2:46 PM EDT GSK plc (GSK) plans to invest more than $800 million to expand its operations in Montgomery County, Pennsylvania, with the project expected to add about 300 jobs over the next five years. Discover more Ethereum investment guide Stablecoin investment platform Accept Payments The investment will expand GSK's operations in Pennsylvania. The expansion is planned over the next five years, with the new jobs tied to the company's Montgomery County operations. John Kim. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to [email protected].

Salem Radio Network
Oct 9th, 2026
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs.

Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs. Oct 9 (Reuters) - GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, Pennsylvania Governor Josh Shapiro's office said on Friday. - The investment will establish a site that combines drug manufacturing, research and development, quality testing and digital operations in Montgomery County. - GSK said construction is planned to begin in 2027 and the project will support both clinical and commercial production of biologic medicines. - The expansion is expected to create more than 300 new jobs and retain about 4,500 existing full-time jobs in Pennsylvania. - The company said the project will include a new commercial-scale biologics manufacturing facility, a research pilot plant and a centralized quality-control laboratory. - Pennsylvania officials said GSK will be eligible for state manufacturing tax incentives tied to the investment. - The Upper Merion expansion and GSK's previously announced Lancaster County facility project together represent nearly $1.7 billion of planned investment in Pennsylvania, according to state officials. - GSK, whose U.S. headquarters is in Philadelphia, said the expansion will help accelerate the development and supply of future medicines. (Reporting by Sahil Pandey in Bengaluru; Editing by Anil D'Silva)

San Francisco Biotechnology Network
Oct 9th, 2026
Chai Discovery announces collaboration with GSK following successful wet-lab evaluation.

Chai Discovery announces collaboration with GSK following successful wet-lab evaluation. SAN FRANCISCO-(BUSINESS WIRE)-Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with GSK. Click here to view original post